Test Price
2,800 AED✅ Home Collection Available
CNNM2 Gene Hypomagnesemia Type 6 Genetic Test in UAE | 2800 AED | DHA Licensed Lab
Executive Summary & Core Metrics
This diagnostic genetic test utilizes Next-Generation Sequencing (NGS) to detect pathogenic variants in the CNNM2 gene, providing a definitive molecular diagnosis for Hypomagnesemia Type 6 (OMIM #611718). The test is designed for individuals and families with a history of magnesium metabolism disorders, enabling personalized clinical management and informed family planning. With a diagnostic sensitivity of 99.9%, all testing is performed at a DHA-licensed, ISO 9001:2015 accredited laboratory facility in Dubai Healthcare City.
- Diagnostic Accuracy: 99.9% sensitivity for identification of clinically relevant CNNM2 variants.
- Collection Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
- Clinical Support: Post-test telephonic guidance by a qualified genetic counsellor to interpret results and outline next steps.
- Insurance Verification: Direct billing confirmation available via WhatsApp: +971 54 548 8731.
Test Overview & Methodology
The test employs targeted NGS enrichment and advanced bioinformatics filtering to sequence the entire coding region and conserved splice-site junctions of the CNNM2 gene. This approach provides superior depth of coverage compared to whole exome sequencing, ensuring detection of mosaic variants and deep intronic mutations. The analytical pipeline adheres to stringent DHA and ISO quality standards for clinical reporting.
| Feature | Our Test (CNNM2 NGS) | Closest Alternative (Whole Exome Sequencing – WES) |
|---|---|---|
| Diagnostic Precision | 99.9% targeted coverage of CNNM2 exons | ~80% average coverage; may miss deep intronic variants |
| Method | Targeted NGS enrichment & bioinformatics filtering | Whole exome capture with incidental finding analysis |
| Speed | 3–4 Weeks | 6–8 Weeks |
| Regulatory Compliance | DHA-Standardized Reporting (Federal Law No. 2 of 2019) | Variable |
Physician Insight & Safety Protocols
“As a Consultant in Medical Genetics, I recognize the profound impact of a precise molecular diagnosis for families navigating inherited metabolic disorders. This targeted NGS test for the CNNM2 gene offers definitive clarity, allowing for tailored therapeutic interventions and accurate risk assessment for at-risk relatives. It is imperative that results are correlated with the full clinical picture and biochemical profile by a qualified specialist.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
Clinical Advisory: Medication & Supplement Management
Do not discontinue, adjust, or initiate any prescribed medications, including magnesium supplements, diuretics, or other electrolyte-modifying agents, without direct supervision of your managing physician. Abrupt changes in therapy can precipitate severe cardiac arrhythmias, tetany, or neurological compromise. This test is for diagnostic clarity and should never replace established medical management plans.
Safety Exclusion Criteria & Emergency Red Flags
- Inability to provide a safe venous blood or DNA sample (severe bleeding disorder, unstable clinical condition).
- Absence of a verified clinical indication or documented family history for CNNM2-related hypomagnesemia.
- Minors under 18 years without parental consent and DHA-approved pre-test genetic counselling.
Emergency Red Flags – Seek Immediate Medical Attention:
- Sudden onset of severe muscle cramps, tetany, or generalized seizures.
- Palpitations, irregular heartbeat, syncope, or pre-syncopal episodes.
- Unexplained progressive weakness, confusion, or altered mental status.
Patient FAQ & Clinical Guidance
1. What does the CNNM2 gene test detect?
This NGS test sequences the entire coding region of the CNNM2 gene to identify pathogenic variants that cause Hypomagnesemia Type 6, a rare autosomal dominant disorder. The comprehensive report includes variant classification, zygosity, and clinical correlation to guide personalized management strategies for affected individuals and at-risk family members.
2. How should I prepare for the genetic test?
No fasting or medication adjustments are required for this test. However, a pre-test genetic counselling session is mandatory to document your family pedigree, discuss implications, and obtain DHA-compliant informed consent. The sample collection involves a standard blood draw or FTA card spot and is quick and painless.
3. What is the turnaround time and how will I receive my results?
Results are delivered within 3 to 4 weeks via a secure, encrypted PDF report. The report includes detailed clinical interpretation, methodology, and variant information. A follow-up telephonic consultation with a genetic counsellor is scheduled to ensure you fully understand the results and their implications for your health and family.
UAE Regulatory & Data Privacy Adherence
All clinical and genomic data processing strictly complies with the UAE’s highest standards for healthcare data protection and patient privacy. Our laboratory infrastructure and operational protocols are designed to safeguard your personal health information throughout the testing lifecycle, from sample collection to result delivery.
- Data Protection: Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) – all genomic data encrypted and processed in-country.
- Health Data Governance: Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields – ensuring secure health information exchange.
- Clinical Safety & Consent: Federal Decree-Law No. 4 of 2016 on Medical Liability – guiding patient consent and clinical responsibility frameworks.
- Laboratory Quality: ISO 9001:2015 Certified Laboratory (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | CNNM2 Gene Sequencing (Hypomagnesemia Type 6) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or FTA Card. VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM). |
| Methodology Used | Next-Generation Sequencing (NGS) with Bioinformatics Analysis |
| ICD-10-CM Code | E83.42 |
| LOINC Code | 82319-8 |
| DHA Facility License & Address | DHA Facility License Number: 1143. Physical Address: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Operated by DNA Labs UAE. |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians